Galectin-3 Allosteric Compounds for Selective Disorder Treatment

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing treatments for medical disorders mediated by galectin-3, such as inflammation, fibrosis, and cancer, often have non-specific interactions leading to side effects and fail to effectively target galectin-3's pathological activities.

Innovation Solution

Development of compounds with a pyrroloquinazoline-ketone structure that allosterically interact with galectin-3 (Gal-3) to modulate its biological activities, reducing side effects by specifically attenuating its pathological functions.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If existing treatments are used to target galectin-3 mediated disorders, then some therapeutic effect is achieved, but non-specific interactions cause side effects

Engineering Contradiction:

Improvetherapeutic effectVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The compound is designed to specifically target the carbohydrate recognition domain (CRD) of galectin-3 through local structural features. The pyrroloquinazoline-ketone core with specific substituents creates a binding interface that matches the CRD binding pocket geometry and chemistry, enabling selective inhibition of galectin-3 while sparing other galectins and reducing off-target effects

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The invention optimizes binding parameters by adjusting the substituent patterns on the pyrroloquinazoline-ketone core. Specific R1, R2, and R3 groups are selected to tune the compound's affinity for the galectin-3 CRD, achieving high potency (low IC50 values) while maintaining selectivity. The parameter optimization includes varying hydrophobic, hydrophilic, and aromatic substituents to match the CRD binding preferences

Inventive Principle:

Principle #35Parameter changes

2Reliability

If existing treatments are used for galectin-3 mediated disorders, then broad galectin inhibition occurs, but this fails to specifically attenuate galectin-3 pathological activities

Engineering Contradiction:

Improveinhibition efficacyVSAvoidselectivity

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The compound structure is locally optimized for galectin-3 CRD binding through specific substituent patterns. The R1 group at position 4, R2 at position 6, and R3 at position 7 of the pyrroloquinazoline-ketone core are independently selected to create a binding profile that discriminates between galectin-3 and other galectins, achieving high selectivity while maintaining potent inhibition of pathological activities

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

Instead of designing compounds that mimic natural ligands and bind to multiple galectins, the invention inverts the approach by designing a structure that exploits unique features of the galectin-3 CRD. The pyrroloquinazoline-ketone scaffold with specific substitution patterns binds to conserved residues in the CRD binding pocket that are particularly important for galectin-3, achieving selectivity through inverted design logic

Inventive Principle:

Principle #13The other way round (Inversion)

Data Source

PatentUS20260060985A1Compounds for the Prevention and Treatment of Medical Disorders and Uses Thereof

Publication Date: 2026.03.05 GALECTIN SCIENCES LLC

AI summary

Aspects of the invention relate to compounds, pharmaceutical compositions, methods for the manufacturing of compounds and methods for treatment of various disorders mediated at least in part by one or more galectins.